Asabys Partners

Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is done through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.

Núria Aloy

CFO

Anna Bellmunt

Associate

Maite Malet

Associate

Guillem Masferrer

Investor

Clara Campàs Moya

Managing Partner

Sylvain Sachot

Principal

Josep Sanfeliu

General Partner

Sáez Borderías Ph.D., Andrea

Senior Investment Associate

17 past transactions

AgomAb Therapeutics

Series B in 2022
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Amelia Virtual Care

Series A in 2022
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.

Cara

Series A in 2022
Cara by HiDoc Technologies is a pharmaceutical company based in Berlin, Germany, focused on improving the lives of patients with chronic digestive diseases. Established in 2015, Cara develops companion digital therapeutics that complement existing treatments for gastrointestinal disorders. One of their key offerings is a personal food and symptom diary, which helps patients track their dietary habits and symptoms, thereby enhancing the overall management of their conditions. By integrating innovative digital solutions with traditional therapies, Cara aims to empower patients and improve their quality of life.

SidekickHealth

Series B in 2022
SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

Splice Bio

Series A in 2022
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Inbrain Neuroelectronics

Series A in 2021
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.

Medlumics

Venture Round in 2021
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.

Koa Health

Series A in 2021
Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions. They create digital tools and resources for mental health that encompass prevention, prediction, and treatment.

SidekickHealth

Series A in 2020
SidekickHealth is a digital therapeutics company focused on preventing and managing chronic diseases. It leverages behavioral economics, gamification, and artificial intelligence to create engaging experiences that facilitate behavior change and enhance health and well-being. The company collaborates with pharmaceutical companies and other organizations to develop personalized lifestyle change programs aimed at improving health outcomes and treatment adherence. Additionally, SidekickHealth connects clinical experts with patient communities and provides data insights to address significant health challenges. Its lifestyle companion app serves as a tool to support individuals on their health journeys.

Splice Bio

Venture Round in 2020
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Origo Biopharma

Seed Round in 2020
Origo Biopharma S.L. is a biotechnology company based in San Cibrao das Viñas, Spain, established in 2017. The company focuses on the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, particularly in gastrointestinal and lung conditions. Origo Biopharma's work addresses significant health disorders, including cancer and fibrosis, through innovative therapeutic approaches.

Ona Therapeutics

Series A in 2020
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

Inbrain Neuroelectronics

Seed Round in 2020
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.

Anaconda BioMed

Series B in 2019
Anaconda Biomed SL, founded in 2015 and based in Barcelona, Spain, is focused on developing advanced healthcare devices, particularly in the field of neurology. The company specializes in creating catheters designed for mechanical thrombectomies, specifically targeting Acute Ischemic Stroke (AIS). Its flagship product, the ANCD BRAIN™, is a novel 3rd Generation Stented Aspiration Thrombectomy System that aims to improve treatment outcomes for patients experiencing AIS. Founded by Dr. Ofir Arad and Dr. Marc Ribó, Anaconda Biomed is recognized as an innovative player in the medical technology sector.

Cara

Series A in 2019
Cara by HiDoc Technologies is a pharmaceutical company based in Berlin, Germany, focused on improving the lives of patients with chronic digestive diseases. Established in 2015, Cara develops companion digital therapeutics that complement existing treatments for gastrointestinal disorders. One of their key offerings is a personal food and symptom diary, which helps patients track their dietary habits and symptoms, thereby enhancing the overall management of their conditions. By integrating innovative digital solutions with traditional therapies, Cara aims to empower patients and improve their quality of life.

Ona Therapeutics

Seed Round in 2019
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

Amelia Virtual Care

Series A in 2019
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.